Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06004817

Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis

Evaluation of Severity in Juvenile Dermatomyositis and Adult-onset Dermatomyositis: a National Multicentric Retrospective Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
Healthy volunteers

Summary

Dermatomyositis (DM) are rare and heterogeneous systemic autoimmune diseases, characterized by the association of muscle inflammation, skin inflammation and vasculopathy. DM concern both adults and children. DM can be life-threatening (interstitial lung disease, infectious complications) and responsible of significant functional disability (muscle weakness). Age of onset appear to be an independent prognostic factor. Juvenile-onset DM is characterized by a higher frequency of calcinosis, skin ulceration and digestive vasculitis. In adults, interstitial lung disease and cancer are more frequent with higher mortality. Data concerning the comparison of the initial severity between juvenile and adult-onset DM are limited. The main objective is to compare global severity between juvenile DM and adult-onset DM at initial diagnosis. Secondary objectives are: * to compare organ-specific severity between juvenile DM and adult-onset DM at diagnosis. * to compare damage during follow-up and at last follow-up between juvenile DM and adult-onset DM. * to compare activity at the last follow-up between juvenile DM and adult-onset DM. * to compare iatrogenic complications between juvenile DM and adult-onset DM.

Conditions

Interventions

TypeNameDescription
OTHERevaluation of clinical severityevaluation of clinical severity

Timeline

Start date
2023-10-01
Primary completion
2024-09-30
Completion
2024-09-30
First posted
2023-08-22
Last updated
2024-08-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06004817. Inclusion in this directory is not an endorsement.